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Abstract 
 
Ingestion of sodium is essential to health, but excess sodium intake is a risk factor for 
hypertension and cardiovascular disease. Defining an optimal range of sodium intake in 
populations has been challenging and controversial. Clinical trials evaluating the effect of 
sodium reduction on blood pressure have shown blood pressure lowering effects down to 
sodium intake of less than 1.5g/day. Findings from these blood pressure trials form the basis 
for current guideline recommendations to reduce sodium intake to less than 2.3g/day. 
However, these clinical trials employed interventions that are not feasible for population-
wide implementation (i.e. feeding studies or intensive behavioural interventions), 
particularly in low and middle-income countries. Prospective cohort studies have identified 
the optimal range of sodium intake to reside in the moderate range (3-5g/day), where the 
risk of cardiovascular disease and death is lowest. Therefore, there is consistent evidence 
from clinical trials and observational studies to support reducing sodium intake to less than 
5g/day in populations, but inconsistent evidence for further reductions below a moderate 
intake range (3-5g/day). Unfortunately, there are no large randomised controlled trials 
comparing low sodium intake (<3g/day) to moderate sodium intake (3-5g/day) in general 
populations to determine the net clinical effects of low sodium intake. Until such trials are 
completed, it is likely that controversy about optimal sodium intake range will continue.  
This working group calls for the completion of large definitive clinical trials to clarify the 
range of sodium intake for optimal cardiovascular health within the moderate to low intake 
range. We support interventions to reduce sodium intake in populations who consume high 
sodium intake (>5g/day), which should be embedded within an overall healthy dietary 
pattern.          
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The impressive reductions in cardiovascular disease (CVD) seen in high income countries 
over recent decades have not been seen in low- and middle-income countries (LMICs), 
where both rates of CVD and, given population growth and ageing, the total disease burden 
are continuing to increase. The success in high-income countries has been attributed to risk 
factor modification among most, although not all of the population, especially reductions in 
smoking, treatment of hypertension and hypercholesterolemia. Yet there are many barriers 
to extending this success to LMICs, reflecting both limited capacity to develop and 
implement healthy public policies in areas such diet and tobacco control and slow progress 
in extending coverage with effective health care.  
There is a renewed imperative to overcome these barriers following the adoption of a 
United Nations High Level Declaration on Non-Communicable Disease (NCD)1 and, more 
recently, the inclusion of a target for reducing by one third premature mortality from NCDs 
through prevention and treatment by 2030 in the Sustainable Development Goals.2 Yet, if 
this ambitious target is to be achieved it will require prioritisation of those measures known 
to be both effective and feasible in LMICs. Given its importance as a risk factor for CVD, such 
measures must tackle the high global burden of hypertension, among the leading modifiable 
risk factors for CVD in all parts of the world.3 While a comprehensive response must include 
expansion of detection and treatment, attention has also focused on the role of sodium 
intake, which has been shown to correlate positively with hypertension, albeit with inter-
individual variation in the strength of the association.4 Reducing sodium content, especially 
when embedded with a healthy cardiovascular diet, exerts short-term reductions in blood 
pressure.  
These considerations have led to the prominence of reducing sodium intake as a strategy for 
CVD prevention in CVD prevention guidelines.5, 6 The WHO recommends a 30% reduction in 
sodium intake worldwide by 2025, irrespective of the baseline mean sodium intake of a 
population, and recommends a mean sodium intake target of <2g/day.7 Public health 
initiatives to reduce excess sodium intake in populations have been adopted by numerous 
countries, but predominantly in high-income countries, with low uptake so far in LMICs. 
However, while there is consistent evidence that high sodium intake (>5g/day) is associated 
with increased CV risk, there is little epidemiologic evidence linking an association between 
moderate sodium intake and increased CV risk (compared to low sodium intake 
recommended by WHO, <2g/day). There is an ongoing scientific debate about the optimal 
lower level of sodium intake for CVD prevention8, but there is an acceptance that a lower 
limit is present, since sodium is an essential nutrient. This implies that there must be a “U”-
shaped relationship between dietary sodium intake and cardiovascular events, but there is 
no consensus of where the minimum risk lies. To add to the complexity, a very recent 
analysis suggested that sodium reduction might only benefit those persons with 
hypertension.9 
There are other major barriers to developing effective interventions for reducing sodium 
intake. First, the absence of accurate, feasible methods to measure sodium intake in 
individuals results in current recommendations (e.g. <2g/day) that are difficult to interpret 
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and implement in clinical practice. There is disagreement about the validity of those 
relatively simple methods that are used for measuring mean intake in populations, such as 
spot urinary sodium measurement and, especially, their interpretation when used to assess 
individual risk. . Second, there are no randomised controlled trials that show that reduction 
of sodium intake, from moderate to low levels, reduces CVD. Third, while a number of  
interventions, both individual, such as education, and population-level, such as 
reformulation, have been proposed, they have no so far been shown empirically to result in 
sustained reductions in sodium intake, particularly in LMICs. Fourth, overall dietary pattern 
is an important determinant of health outcomes, and recommendations based on sole 
nutrients need to consider the effect on overall dietary pattern, and regional variations in 
dietary patterns (e.g. sources of sodium intake vary by region, and within regions).  
The current statement does not seek to replicate prior guidelines on sodium intake, but 
attempts to propose a practical approach to sodium intake that can inform public policy and 
clinical practice in adults in LMICs. We summarise knowledge-gaps in our understanding of 
association between sodium intake and health, and recommend future areas of research 
focus in LMICs.  
 
 
Physiology of Sodium 
Sodium is an essential nutrient, required for numerous physiologic processes. It is tightly 
regulated by numerous physiologic (renal, endocrine, immune) systems which act to 
maintain serum sodium within normal range. Sodium exchange with potassium is a key part 
of the action potential of human cells. In most people, normal kidneys are capable of 
excreting large amounts of sodium, or excrete almost no sodium, in settings of high and low 
sodium intake respectively. Niche populations with very low sodium intake have been 
studied, and have a low prevalence of hypertension10, although long-term effects of low 
intake on health have not been evaluated as mean life expectancy in these population was 
short (~40 years). There is a positive association between increasing sodium intake and 
blood pressure, in observational and experimental research studies, with inter-individual 
variability. Reductions in sodium also appear to affect cardiovascular dynamics, with animal 
models demonstrating low sodium intake associated with attenuated pressor responses 
during stress (e.g. septic shock). 11, 12 Our understanding of the physiology of sodium intake, 
storage and excretion is continuing to evolve. For example, recent evidence suggests that 
sodium excretion demonstrates cyclic variations, and the majority of sodium is stored in 
skin, subcutaneous lymphatic networks and in muscle, and partly regulated by the immune 
system.13, 14 A recent studies also suggest that sodium that is still well within the “normal” 
range may be more hazardous than previously thought in hospitalised subjects.15 These 
observations raise issues related to measurement of sodium and need to gain better 
understanding of potential effects of manipulating sodium intake on the immune system.   
 
Measurement of Salt Intake 
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Individual Level Assessment of Sodium Consumption: A prerequisite for effective 
programmes to modify risk factors, is an ability to accurately measure the exposure using 
simple methods (e.g. blood pressure, cholesterol, smoking). A key obstacle to making 
quantitative individual-level recommendations on sodium intake targets, is the lack of valid 
and reliable methods to objectively quantify sodium intake in individuals. At present, there 
is no routine approach to accurately measuring sodium intake in individuals. Accurate 
objective measurement requires multiple 24-hour urine collections, which is impractical in 
clinical practice.16 Therefore, while guidelines may recommend an intake of sodium 
<2.3g/day, this target is relatively meaningless to both clinician and patient, as it is not 
supported by an available objective measurement. In contrast, recommendations on blood 
pressure targets are based on simple measurements, which are suitable for both screening 
and monitoring change over time, which are readily interpreted and implemented by 
clinician and patient, and can be applied in all settings given the ease of blood pressure 
measurement. In contrast to other dietary recommendations (e.g. increased consumption of 
fruits and vegetables) where intake is directly observable, self-assessment of sodium intake 
range is poor, which may be related to the fact that much of sodium intake is hidden 
(embedded within foods, particularly in high income countries), and the accuracy of self-
predicted sodium intake appears to be independent of knowledge and attitudes to sodium 
intake17. Even subjective categorisation of individuals into high, medium and low sodium 
intake is poor, although dietary questionnaires are generally good at identifying groups and 
individuals who consume high sodium, but these require validated questionnaires to specific 
populations as different populations have distinct dietary patterns. Moreover, standard 
food composition tables developed in one setting may not apply to others, where the same 
descriptors may include differently constituted foodstuffs. 18The implication, therefore, is 
that a policy targeting individual consumption should incorporate recommendations for 
individuals, which are not dependent on numeric targets, but based on practical assessment 
of diet to identify high sodium foods and those consuming high sodium diets. In such 
individuals, reduction of sodium intake can, in theory, be facilitated by recommendations to 
avoid/reduce sodium in food preparation and at the table, and avoid (or replace) specific 
foods that are high in sodium, rather than targeting a specific quantitative target for sodium 
intake. However, such an approach requires a detailed knowledge of food items with a high 
sodium content, taking account of the dietary variations  that exist not only between 
countries but also among different regions of a country. Even with common foods, such as 
breads, sodium content can vary widely, but there are also many foodstuffs that are 
common in some settings but rare in others (e.g. salted fish such as bacalhau and its 
variants). Examples of dietary screening tools exist, but very few have been validated in 
LMICs.   
 
Population-level Assessment of Sodium Consumption: Employing multiple 24-hour urinary 
collections is considered to be the reference standard for measuring sodium intake in 
populations, but challenging to complete in large population studies . Recent research has 
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suggested that use of spot urine, or particularly fasting urine samples, which employ a 
formula-derived approach, appears suitable to estimate mean intakes at a population-level 
or subdivide large populations into those who, on average, have high, moderate and low 
sodium intakes.19 Spot or fasting urine measurement has offers the potential to achieve 
more representative samples in a population (external validity), since use of 24-hour 
collections are burdensome and associated with a high rate of non-adherence for complete 
collections. This creates an inherent risk of selection bias (i.e. individuals who are adherent 
with 24-hour collections differ from those who are not). Intraclass correlation (ICC) for single 
urine-formula derived estimates of 24-hour urinary sodium excretion are good (0.71 in 
largest validation study of fasting urine) and comparable to the ICC for single office blood 
pressure measure compared to 24-hour ambulatory blood pressure measurements. 
However, while there is acceptance that blood pressure measured during office visits is 
suitable for large epidemiologic studies, there is debate about whether spot or fasting 
urines are appropriate in large epidemiologic studies to estimate mean intake or report on 
association with clinical outcomes. The WHO does, however, consider spot/fasting urine 
assessment of sodium intake in populations to be appropriate for measuring mean sodium 
intake. Dietary questionnaires, using either food frequency questionnaire or 24-hour dietary 
recall, are more convenient but more time-consuming to complete than single urine 
measures. Dietary questionnaires require validation in population with distinct dietary 
patterns and different sources of sodium intake. Generally dietary assessments provide a 
lower, and less reliable, quantification of sodium intake, compared to urinary 
measurements, which presents especial challenges for between-study comparisons. A main 
advantage of dietary assessment is the identification of food items that are high in sodium, 
and measurement of overall dietary quality to guide other types of dietary 
recommendations.  
 
Regional Variations in Sodium Intake 
Globally, the mean intake of sodium is estimated at 3.95g/day by the Global Burden of 
Disease (GBD) collaboration, in a meta-analysis of surveys from 187 countries, using 24-hour 
urine collections.20 Intakes were highest in East Asia, Central Asia and Eastern Europe (mean 
>4.2 g/day) and in Central Europe and Middle East/ North Africa (3.9–4.2 g/day). Mean 
intakes in North America, Western Europe and Australia/New Zealand ranged from 3.4 to 
3.8 g/day. Intakes were lower (<3.3 g/day), but more uncertain, in sub-Saharan Africa and 
Latin America. Between 1990 and 2010, there was a suggestion of slight increases in overall 
sodium intakes. These regional variations are consistent with reports from the PURE study 
involving 18 countries which used 24-hour formula-derived estimates from fasting morning 
urine specimens, which was published after this systematic review.21  
In addition to regional variations in mean sodium intake, there are important variations in 
the degree to which intake is from discretionary and non-discretionary sodium, which has 
implications for developing approaches to reduce sodium intake, especially whether priority 
should be given to a population versus individual-level interventional approach. The 
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proportion of sodium intake from discretionary sources in North America and Europe is 
about 10-25%, compared to about 70% in China and other countries in Asia, other parts of 
Asia and Africa. Therefore, in countries with high non-discretionary use, reducing sodium in 
processed or pre-packaged foods through reformulation is more important, whereas in 
countries with high discretionary use, reducing salt during cooking and added at table 
appear to be the most relevant priority targets. Thus, knowledge of the main sources of high 
sodium intake is a mandatory step in developing country-specific approaches to reducing 
high sodium intake.  
 
Socioeconomic variation in sodium intake 
Studies in several countries have found that those with lower levels of education or living in 
disadvantaged areas have higher salt intakes and, in England, exhibited less change during 
the course of a national salt reduction campaign.22, 23 
 
Effect of Reducing Sodium Intake on Blood Pressure  
Evidence of an association between sodium intake and blood pressure comes from 
numerous lines of evidence, including observational research and results of clinical trials 
reporting a reduction in blood pressure following lowering of sodium intake. In these 
studies, there is evidence of variations in the associations among different subgroups of 
people, with a stronger association in older age groups, people with hypertension and those 
consuming low potassium diets.  
 
Clinical Trials: Over 40 clinical trials have evaluated the effects of reducing sodium intake on 
blood pressure, and other biomarkers. Of these, most (>95%) were short-term trials (<6 
months).34,35  
Of short-term trials, the findings from the DASH trial have exerted greatest influence on 
current guidelines, and demonstrated short-term reductions in blood pressure (30 days) 
with reductions of sodium intake to under 1.5g/day.24 In the DASH trial, all foods were 
provided to participants (i.e. this was a feeding study), and was therefore conducted in a 
highly controlled environment which cannot be replicated in routine daily life. Such low 
intake levels have not been achieved in routine clinical practice (i.e. after routine clinician 
recommendations), or even with intensive counselling interventions in randomised 
controlled trials. Whereas the short-term nature of the clinical intervention is known, the 
long-term effect of this diet on blood pressure and outcomes has not been established in 
RCTs.  
The TOHP-II trial is the largest clinical trial (n=2382) evaluating the effectiveness of a 
counselling/educational intervention to reduce  sodium reduction and thus blood pressure, 
with a mean duration of follow-up of 36 months.25 The trial was a 2X2 factorial that also 
evaluated a behavioural change intervention for weight loss. At 18 months, a mean sodium 
of 3.1g/day (3.2g/day at 36 months) was achieved in the intervention group (versus) 
compared to mean intake of 3.9g/day (4.0g/day at 36 months) in the control group. The 
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difference in systolic blood pressure between sodium intake groups was 2.9 mmHg at 6 
months, 2.0mmHg at 18 months and 1.2 mmHg at 36 months, with a reduction in the 
incidence of hypertension which also diminished over time, with a risk ratio of 0.61 (P=0.04) 
at 6 months, 0.88 (P=0.28) at 18 months, and 0.82 (P=0.05) at study end.33 This trial suggests 
that a 0.8g/day difference in sodium intake lowered blood pressure by 2 mm Hg. While this 
may have been the case,  repetitive urine collections were variable in TOPH II, imprecisely 
documented, and the goal in TOPH II was not to provide a long-term study of cardiovascular 
events as the outcome. Finally, the circaseptan (7 day) variability in daily sodium excretion 
was unknown at the time of TOPH II.12   
The TONE trial evaluated a similar intervention to TOHP-II in older adults (60-80 years) with 
controlled hypertension (n=975). Ninety days after introduction of the intervention, systolic 
blood pressure was reduced by 3.4mmHg. Withdrawal of antihypertensive therapy began at 
90 days, and the proportion of patients requiring antihypertensive therapy  was lower in the 
sodium intervention group compared to control (24% versus 38%).26  These data suggest 
that despite sustained maintenance of most of the difference in sodium intake between 
intervention and control, the differences in blood pressure are attenuated over time, and 
large trials with extended duration of follow-up are needed to assess the long-term 
antihypertensive effect of sodium reduction in this sodium intake range. In each of these 
clinical trials, the control group did not include a control intervention (e.g. dietary 
counselling that did not include advice on salt intake), which means that they were unable 
to determine the effects of sodium reduction, independent of other dietary changes (e.g. 
increase in fruit/vegetable intake). An educational intervention targeting school children in a 
cluster randomized controlled trial in China (28 schools, 832 family members) reported a 
reduction in sodium intake (0.8g/day in adults with mean intake of sodium 4.7g/day), and, 
while blood pressure increased in both the intervention and control groups during follow-
up, the increase was significantly less in the intervention group.27  
There have been several meta-analyses of clinical trials evaluating sodium reduction for 
blood pressure reduction.28 29 In a recent meta-analysis of 34 blood pressure clinical trials 
(n=3230), a reduction in sodium intake (1.76g/day difference in mean change between 
intervention and control) was associated with a mean 4.2/2.1mmHg reduction in blood 
pressure. Among participants with hypertension, the blood pressure reduction was greater 
(-4.06/2.26mmHg) compared to those without hypertension (-1.38/0.58mmHg).19 Duration 
of follow-up may be an important determinant of treatment effect, which was explored in 
another meta-analysis of blood pressure trials that included 36 trials.34,35 In trials of <3 
months, 3-6 months and more than 6 month’s duration, blood pressure reductions were 
4.07/1.67mmHg, 1.91/1.33mmHg and 0.88mmHg/0.45mmHg respectively. These data 
demonstrate the challenges faced by counselling interventions in maintaining adherence to 
reduced sodium intake from moderate to low intake levels over time, even when dietary 
counselling is relatively intense, and raise a suspicion that the blood pressure lowering 
effects of moderate sodium reduction may diminish over time, based on findings from the 
largest long-term trial included in the review (TOHP trial).  
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A number of clinical trials have evaluated use of salt substitutes (low-sodium salt) usually 
involving a reduction of the proportion of NaCl proportion in total salt to about 45-65%, and 
replacing it with KCl or MgSO2. This is especially applicable in populations with high 
discretionary salt use (e.g. China). A meta-analysis of these clinical trials (5 clinical trials, 
n=1,974) reported a reduction in blood pressure (-4.9/1.5mmHg) with use of salt 
substitutes, ranging from 6 months to 2 years. A recent large cluster randomised controlled 
trial in China (China Rural Health Initiative-Sodium Reduction Study) randomised 120 villages 
to either intervention (health education and access to salt substitution, with 30 of the 60 
intervention villages also receiving a price subsidy as salt substitute is more expensive than 
regular salt) or control.30 Among 1,295 participants in the intervention villages (1,063 with 
urine assessment), there was a 0.3g lower sodium intake (P=0.03) on follow-up compared to 
control (1,272 participants, 1,001 with urine assessments). There was no significant 
difference in change in blood pressure (-1.0/0.8mmHg, p=0.39 and 0.34 respectively).  A 
large cluster randomised controlled trial of 600 villages with over 21,000 participants is 
being undertaken in China designed to evaluate the effects of salt substitution on stroke risk 
in individuals at high risk of stroke, over 5 year’s follow-up (SSaSS trial). Findings from the 
SSaSS trial may have important implications for population-level approach to prevention of 
stroke in communities with high discretionary sodium intake. However, as this trial 
evaluated salt substitution in a region with high sodium intake, it will be unable to 
determine the effect of lowering sodium intake from moderate to low intake levels, and 
unable to determine the independent effect of sodium reduction from increased potassium 
intake on stroke risk.  
 
 
 
Effects of Sodium Intake on Cardiovascular Biomarkers 
 The level of sodium intake affects the renin-angiotensin-aldosterone system (RAAS), 
with low sodium intake resulting in activation in RAAS shown in short-term studies.31, 32 
Activation of the sympathetic nervous system with an impairment of reflex homeostatic 
control has been reported.33, 34 However, the clinical relevance of this observation is 
uncertain, since some effective antihypertensive therapies that lower blood pressure and 
CVD also increase renin levels and sympathetic nerve activity levels, and it is unclear 
whether these effects persist during long-term low-sodium intake. It does however 
demonstrate that sodium intake exerts endocrine feedback effects at sodium intakes below 
about 3g/day. Sodium intake also appears to exact effects on immune and inflammatory 
biomarkers, whose relevance remains unclear. Moreover, in prospective cohort studies, the 
magnitude of association between sodium intake and cardiovascular outcomes is only 
modestly attenuated after adjustment for blood pressure, suggesting that the potential 
adverse effects on cardiovascular outcome are only partly attributable to changes in blood 
pressure. These data suggest that the effects of changes in sodium intake on health are 
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complex, and could be mediated through a number of different physiologic mechanisms, 
including, but not isolated to, blood pressure.  
 
Effect of Reducing Sodium Intake on Cardiovascular Disease  
Clinical Trials: No randomized controlled trials (RCT) have been undertaken to determine 
specifically whether low compared to moderate sodium intake reduces the incidence of CV 
events or death (compared to moderate intake). Meta-analyses of those blood pressure 
trials that reported CV events do not report a significant reduction in CVD with lowering 
sodium intake, but these trials are underpowered to detect moderate risk reductions. An 
extended observational follow-up of the TOHP I and II trials reported on the risk of death 
and CV events (composite of myocardial infarction, stroke, coronary revascularization or 
cardiovascular death) during 10-15 years after completion of the trials, which reported a 
reduction (OR 0.75; 99%CI 0.59-0.99) on adjusted analyses, but not in unadjusted analyses. 
However, there were very high rates of loss to follow-up for CV outcomes, as this was 
opportunistic rather than planned extended observation follow-up. For all-cause mortality 
(100% follow-up), there was complete determination of outcome, and no significant 
association. In summary, no individual trial, or combination of all longer-term trials, is 
sufficiently powered to detect whether  moderate risk reduction in CVD associated with 
reducing sodium intake While there are also no large randomised controlled trials 
demonstrating a reduction in CVD with reducing high sodium intake (>5g/day), the 
consistency of findings from blood pressure trials and observational studies provides 
evidence that reducing high sodium intake will reduce blood pressure and CVD, in the 
absence of harm, especially in people with hypertension.   
A small cluster randomized controlled trial (n=1,981) conducted in 5 kitchens of veteran’s 
retirement homes in Taiwan, in which participants increased potassium consumption and 
reduced sodium consumption through use of potassium-enriched salt, found a reduction in 
cardiovascular mortality (HR 0.59; 95%CI 0.37-0.95) in those assigned to the higher 
potassium group.35 The trial (which utilised cluster randomisation) was analysed using 
individual-level (inappropriately), rather than cluster-level data. Moreover, in that trial, 
sodium intake was estimated to be reduced from 5.2g/day to 3.8g/day, with a 
proportionately larger effect on potassium intake than sodium intake. Thus, it is necessary 
to await the findings of the SSaSS trial to ascertain the effectiveness of sodium reduction 
through salt substitution intervention in the setting of high levels of discretionary salt use.  
 
Prospective Cohort Studies: Among individual studies which have included a defined group 
with high sodium intake (>5g/day), most report an overall increased risk of CV events in 
these groups.36 However, in many prospective cohort studies, urinary samples were 
collected for a variety of purposes, and not specifically to measure sodium intake. Meta-
analyses of prospective cohort studies have generally compared the lowest quantile of 
sodium intake with highest quantiles.37 In the most recent of these meta-analyses, there 
was a significant association between highest sodium intake quintile and stroke (RR 1.24; 
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95%CI 1.08-1.43) and fatal coronary events (RR 1.32; 1.13-1.53), but not all-cause mortality 
(RR 1.06; 0.94-1.20) or all CVD mortality (1.12; 0.93-1.34). In another meta-analysis38 that 
compared high (>5g/day) sodium intake to moderate (2.7-5g/day) sodium intake, there was 
an increased risk of all-cause mortality (HR 1.16; 1.03-1.30), CVD (HR 1.12; 1.02-1.24), stroke 
(HR 1.18; 1.05-1.33) and heart disease (HR 1.17; 1.08-1.27). In that meta-analysis43  a 
comparison of low sodium intake (<2.7g/day) with moderate/usual intake (2.7-5g/day) 
intake found that moderate sodium intake was associated with a lower risk of all-cause 
mortality (0.91; 0.82-0.99) and all CVD mortality  (HR 0.90; 0.82-0.99), compared to low 
intake (<2.7g/day). Following  these meta-analyses, the PURE study, the largest 
international study (n=101,945, 3.7 years follow-up) to evaluate the association between 
sodium intake (based on formula-derived 24-hour sodium excretion from a fasting urine 
sample) reported a J-shaped association between sodium excretion and CVD incidence and 
mortality, consistent with findings from the most recent meta-analysis.39 In contrast to the 
earlier studies that were included in the meta-analysis, the PURE study had greater 
representation from LMICs and so are probably most relevant to informing policy in LMICs. 
One study, which analysed an extended follow-up of the control group (n=2,275) in the 
TOHP trial, reported a linear association between sodium intake and CVD, but the 
proportion of the population with low sodium intake was small (n=235) with wide 
confidence intervals in the lower intake range.40   
Observational studies, even when conducted with methodologic rigour and analysed to 
optimally adjust for measured confounders, have inherent limitations, including residual 
confounding and reverse causation.41 There are two new reports to be published soon. In 
the CRIC cohort, repeated 24-hr urine collections were used to estimate sodium excretion 
wherein sodium was strongly related to CVD events, for sodium intakes over 4.5g/day42 . In 
another meta-analysis of observational studies that employed the Kawasaki formula and 
created two groups based on presence or absence of hypertension, a direct relationship 
between sodium excretion and CVD was noted in the hypertensive group for high vs. 
moderate sodium excretion but an inverse relationship was noted for both the hypertensive 
and normotensive groups9 .  While the totality of evidence from observational studies raise 
caution about the safety of reducing sodium intake to very low levels, and none report a 
significantly lower risk of CVD for low versus moderate sodium intake, definitive evidence 
can only come from large randomised controlled trials.   
There are no prospective randomized controlled trials (RCT) with hard major adverse cardiac 
events (MACE) cardiovascular endpoints. TOPH II and TONE were never conceived as such. 
Admittedly, an individual-level RCT with sodium reduction as the only variable would be 
exceedingly difficult in free-living individuals for reasons made clear above.  
 
What Factors Modify the Association Between Sodium Intake and CVD? 
Hypertension: Clinical trials and observational studies have generally reported a greater 
blood pressure lowering effect of sodium reduction among individuals with hypertension. 
Two prospective cohort studies have reported an effect-modification of hypertension for 
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CVD. In the PREVEND study, (n=7543) 36, an association between high sodium intake and 
CVD was confined to participants with baseline hypertension. In the PURE cohort45, a 
significant interaction between baseline hypertension and sodium intake (P=0.02) was 
found, with the increased risk of CVD associated with high sodium intake only found in 
those with hypertension. However, the increased risk of CVD and mortality at sodium intake 
below 3g/day was seen in those with and without hypertension.  
Diabetes Mellitus: There is no convincing evidence that the presence of diabetes mellitus 
modifies the association between sodium intake and clinical outcomes, although reports of 
an increased CV risk with low sodium intake have been prominent in patients with diabetes.   
Obesity: Two studies reported an increased risk of higher sodium intake among participants 
with increased BMI (but not in the entire cohort).43, 44  
Other Dietary Factors: Many dietary factors (e.g. fruit, vegetable and meat intake) and 
dietary patterns (e.g. prudent diet, Mediterranean diet) have been associated with differing 
risk of CVD.45, 46  
Overall diet quality appears to be an important modifying effect, supported by evidence 
from the DASH-Sodium trial, which reported a greater blood pressure lowering effect 
among those with a healthy CV diet, compared to a less healthy one. 
In this regard, potassium intake may modify the association between sodium intake, blood 
pressure and CVD.47 Epidemiological studies have also reported that increased potassium 
intake is associated with reduced risk of CVD, particularly for stroke.48, 49 While the effect of 
dietary sodium is likely to be the same regardless of source, certain sources may provide 
other nutrients and micro-nutrients with consequences for CVD, creating potential for 
confounding. For example, in some regions, high sodium intake may be primarily from 
processed foods and food types such as fried foods, especially in high-moderate income 
countries. In other regions, the main sources of high sodium intake may include salted fish 
and vegetables, which, independently, do not increase CV risk.  
Cardiovascular Disease: The blood pressure lowering effects of reducing sodium intake 
appear similar in populations with and without CVD, although most studies have been in  
populations without CVD. The relative association between sodium intake and CVD also 
appear to be similar, although rates of events are higher in populations with prior CVD.50, 51 
Patients with heart failure represents a unique population, where the effects of low sodium 
intake require further study (and are dealt with in another section). The PREVEND study 
reported pro-BNP to be an effect-modifier of the association between sodium intake and 
CVD.  
Genetic Determinants of Salt Sensitivity: Some individuals are more sensitive to the 
hypertensive effects of increased sodium intake, termed ‘salt sensitivity’52. About 30-50% of 
persons with hypertension are thought to be salt-sensitive. An intensive area of research 
seeks to identify genetic polymorphisms that are associated with both hypertension and 
‘salt sensitivity’.53 The clinical relevance of salt sensitivity is uncertain, as definition and 
identification of salt sensitive populations lack clarity, although people who develop 
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hypertension appear to have a greater increase in blood pressure for a given increase in 
sodium intake compared to those who do not develop hypertension.   
 
National Interventions to Reduce Sodium Intake  
A recent systematic review examined 39 state and community level interventions, which 
included nutrition education programmes, public education campaigns, changes to the food 
environment, other 'novel' approaches and multifaceted approaches.54 It concluded that 
there was some evidence of effectiveness but most studies had methodological limitations 
and more robust evaluations were needed.  
The WHO has published guidelines on approaches to develop, implement and monitor 
sodium intake, and integrate them with approaches to eliminate iodine deficiency. 
However, such programs have been adopted or implemented55 mainly in higher income 
counties. Interventions can be divided into those seeking to change individual choices, such 
as consumer education and front of pack labeling, and those limiting the choices that are 
available, such as reformulation or changes to cooking methods in institutional settings (e.g. 
schools, workplaces). The latter can be further divided into those that are voluntary and 
those that are imposed through legislation. 
In some of these countries, reductions in mean sodium intake has been reported, which was 
most apparent in countries with a relatively higher mean intake of sodium (>4g/day), but 
less evidence is available in countries with mean intake in the moderate range56. However, a 
separate meta-analyses completed by the GBD did not report reductions in sodium intake in 
any region from 1990 to 2010. In most regions of Africa and Asia (with exception of China), 
no public health strategy has been developed to reduce sodium intake. In China, where 
mean intake of sodium is high (4.8g/day), there is evidence of a reduction in mean sodium 
intake over time (from 6.7g/day to 4.8g/day from 1991 to 2009), which has been largely due 
to reduction in discretionary salt intake. However, the reduction in discretionary intake has 
been countered by a recent increase in consumption of processed foods and non-
discretionary salt intake. This is not unique to China and reflects the increasing globalization 
of the food industry. This has led to pressure for reformulation to reduce sodium content 
which can, as noted above, be voluntary or imposed through legislation or regulation. 
Unsurprisingly, the food industry argues for voluntary agreements and for a major role in 
developing standards, although even in high income countries progress has been mixed 
unless there is a credible threat of regulation.57 58There is now extensive evidence from 
other areas of public health that voluntary approaches more generally are often ineffective, 
with industry emphasizing measures that impose least costs on it rather than those that 
work, and committing to measures that it is already implementing. 59, 60 
Consequently, some countries have implemented legislative intervention to reduce sodium 
intake, including mandatory salt targets (e.g. Paraguay), taxation on high salt foods (e.g. 
Portugal), regulations to ensure front of pack labeling (e.g. Ecuador, Indonesia) and 
standards for salt in procurement policies (e.g. Argentina, Latvia). Other LMIC are 
developing approaches to inform strategies to reduce sodium intake.61 
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SUMMARY AND RECOMMENDATIONS  
 
1. RESEARCH TO ADDRESS KNOWLEDGE GAPS  
 
Measuring Sodium Intake? 
 There is a need to identify simple methods to objectively measure sodium intake 
that are valid and reliable and applicable in diverse populations. The absence of such 
measures is an obstacle to implementing strategies to reduce sodium intake, and 
evaluating different sodium intake targets for cardiovascular prevention.    
 There is a need to complete studies to identify key sources of high sodium intake, 
discretionary and non-discretionary, in different regions of the world with distinct 
dietary patterns, particularly in LMICs. It is necessary to develop simple screening 
methods to identify populations consuming high sodium intake, which can be 
administered by healthcare workers and self-assessed.  
 
Feasibility of long-term low sodium intake?  
 Despite recommendations for population-wide low sodium intake, it has not been 
shown that sustained low sodium intake is feasible in free living individuals. Examples of 
reducing sodium intake from high to moderate intake levels have been reported in 
countries (e.g. Finland, Japan). We recommend studies to identify simple/generalizable 
interventions to reduce sodium intake to low intake levels, which would enable studies 
to assess the feasibility and effectiveness of such sodium intake targets in the long-term 
(e.g. over 2 years). 
 We note the particular paucity of studies of from LMIC in different regions of the 
world (e.g. Africa, Latin America, India or SE Asia) and we recommend that such studies 
should be conducted in each region given the marked variations in diet and cooking 
methods in these regions. Such studies can also document whether the reductions in 
sodium will also lead to similar reductions in blood pressure, in populations consuming 
different diets. In addition, such studies should identify regional and local barriers to 
sodium intake reduction.  
 
Effect of long-term low sodium intake reduce the risk of cardiovascular disease and death?  
 We support the conduct of definitive randomized control trials, comparing low 
sodium intake (<2.4g/day) to moderate intake (2.4g-5g/day) on cardiovascular events 
and mortality. Currently, there is insufficient information to reliably answer this 
question, as there are competing lines of evidence from blood pressure trials (which 
report a reduction in blood pressure) and epidemiologic studies of association between 
sodium intake and cardiovascular events (some of which report a higher risk associated 
with low sodium intake).  
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SUMMARY AND RECOMMENDATIONS  
 
2. PRACTICAL RECOMMENDATIONS (BASED ON CURRENT EVIDENCE) 
 
A. POPULATION-LEVEL  
 
Measuring Sodium Intake (Population) 
 
 Measure sodium intake in the population (average intake and distribution), to 
determine current and future (monitoring) sodium intake. Measuring and monitoring of 
sodium intake using formula-derived estimates of 24-hour sodium excretion from 
morning fasting urines are reasonable, and ensure standardized measurement in 
different regions. Employ dietary assessments to determine key sources of sodium 
intake. 
 
Sodium Intake Target (Population) 
 
 Sodium is an essential nutrient, and is a dietary requirement for all humans, and 
should be included in a healthy balanced diet. Excess sodium intake is an important 
determinant of hypertension and CV risk.  
 For population-wide recommendation of sodium intake, lowering sodium intake 
from high intakes (>5g/day) to moderate intakes (3-5g/day) is associated with lower 
blood pressure and lower CVD in observational studies. Although there are no RCTs 
demonstrating a reduction in CVD with lowering sodium intake from high to moderate 
levels, the consistency in data from observational studies (reporting a lower CV risk in 
populations consuming moderate intake compared to high sodium intake) and clinical 
trials (reporting a reduction in blood pressure) support reducing high sodium intake in all 
populations.  
o In populations with high mean sodium intake (e.g. China), a population-wide 
approach to sodium reduction is probably appropriate, with a target of reducing 
mean sodium intake by 30% (WHO).  
o In countries/populations where mean intake is moderate (e.g. 3-5g/day, a 
targeted approach of reducing salt in those consuming high salt intake is 
appropriate, especially among those with hypertension. 
 Reducing mean sodium intake from moderate intake to below 3g/day is expected to 
reduce blood pressure, but the effects on CVD and mortality are uncertain, especially in 
populations who do not have hypertension. 
 Recommendations on diet should be included within an overall recommendation for 
healthy dietary pattern, rich in fruit and vegetables (e.g. Mediterranean diet) and other 
lifestyle recommendations.  
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Reducing Sodium Intake (Interventions in Populations) 
 Existing interventions to reduce high sodium intake in populations appear 
reasonable, including educational interventions in in public institution settings (e.g. 
School Edu-Salt), food reformulation, consumer education, front of pack labelling and 
intervention in public institution settings. Such interventions are expected to reduce 
sodium intake from high to moderate intake ranges, based on prior ecological research 
studies, and community-level education intervention trials. Educational interventions 
should target overall dietary pattern but are not a substitute for population level 
measures. Educational interventions should be informed by research studies of local 
dietary patterns, and dietary sources of high sodium.   
 Current evidence supports the safety of low-sodium salt substitutes, although a large 
ongoing clinical trial to determine its effectiveness in reducing stroke risk is pending 
(SSaSS Trial).     
 
 
 
B INDIVIDUAL-LEVEL  
 
Measuring Sodium Intake (Individual) 
 
 Practical measurement of sodium intake requires dietary assessment, as there is no 
practical objective measurement of sodium intake.  
 Screening of individuals, especially those with hypertension, for high sodium intake 
factors (e.g. adding salt in cooking, adding salt in table, excess consumption of processes 
foods high in salt content) is a practical approach to identifying individuals consuming 
high sodium diets.   
 
Sodium Intake Target (Individual) 
 
 Sodium is an essential nutrient, and is a dietary requirement for all humans, and 
should be included in a healthy balanced diet. Excess sodium intake is an important 
determinant of hypertension and CV risk.  
 As there is no practical method to objectively and accurately measure sodium intake 
in individuals, we recommend avoiding a numeric target in individual counselling. 
Rather, individuals should be screened for their consumption of food patterns. Food 
items known to be associated with high sodium content should be reduced, or 
substituted, and reductions/substitutions recommended.  Such an approach requires 
knowledge of main sources of high sodium intake (discretionary versus non-
discretionary) and high sodium food items that are consumed commonly in the setting 
in question. 
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Reducing Sodium Intake Target (Intervention in Individuals) 
 
 Individual-level counselling/educational interventions that have been shown to 
reduce sodium intake in clinical trials are impractical for primary care settings, although 
these have targeted reducing sodium intake from moderate to low sodium intake levels.  
 Family and community-level interventions have been shown to reduce high sodium 
intake, although the available evidence suffers from methodological limitations.  
 Current evidence supports the safety of low-sodium salt substitutes, although a large 
ongoing clinical trial to determine its effectiveness in reducing stroke risk is pending 
(SSaSS Trial).     
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